| Code | CSB-RA006920MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to JS015, targeting Dickkopf-1 (DKK1), a secreted glycoprotein that functions as a key antagonist of the canonical Wnt/β-catenin signaling pathway. DKK1 binds to LRP5/6 co-receptors on cell surfaces, preventing Wnt ligand interaction and thereby inhibiting Wnt-mediated cellular processes essential for bone formation, tissue homeostasis, and cellular differentiation. Elevated DKK1 expression is implicated in multiple pathological conditions, including osteoporosis, multiple myeloma, and various solid tumors where it contributes to osteolytic bone lesions and creates an immunosuppressive tumor microenvironment that facilitates cancer progression.
JS015 (also known as DKN-01) represents a clinical-stage therapeutic antibody that has been investigated for its potential to restore Wnt signaling and modulate bone remodeling and anti-tumor immunity. This biosimilar antibody provides researchers with a valuable tool for investigating DKK1-mediated mechanisms in bone metabolism, cancer biology, and Wnt pathway regulation studies, supporting translational research in oncology and metabolic bone diseases.
There are currently no reviews for this product.